Neurocognitive signs in prodromal Huntington disease

PREDICT-HD is a large-scale international study of people with the Huntington disease (HD) CAG-repeat expansion who are not yet diagnosed with HD. The objective of this study was to determine the stage in the HD prodrome at which cognitive differences from CAG-normal controls can be reliably detecte...

Full description

Saved in:
Bibliographic Details
Published inNeuropsychology Vol. 25; no. 1; p. 1
Main Authors Stout, Julie C, Paulsen, Jane S, Queller, Sarah, Solomon, Andrea C, Whitlock, Kathryn B, Campbell, J Colin, Carlozzi, Noelle, Duff, Kevin, Beglinger, Leigh J, Langbehn, Douglas R, Johnson, Shannon A, Biglan, Kevin M, Aylward, Elizabeth H
Format Journal Article
LanguageEnglish
Published United States 01.01.2011
Subjects
Online AccessGet more information

Cover

Loading…
More Information
Summary:PREDICT-HD is a large-scale international study of people with the Huntington disease (HD) CAG-repeat expansion who are not yet diagnosed with HD. The objective of this study was to determine the stage in the HD prodrome at which cognitive differences from CAG-normal controls can be reliably detected. For each of 738 HD CAG-expanded participants, we computed estimated years to clinical diagnosis and probability of diagnosis in 5 years based on age and CAG-repeat expansion number (Langbehn, Brinkman, Falush, Paulsen, & Hayden, 2004). We then stratified the sample into groups: NEAR, estimated to be ≤9 years; MID, between 9 and 15 years; and FAR, ≥15 years. The control sample included 168 CAG-normal participants. Nineteen cognitive tasks were used to assess attention, working memory, psychomotor functions, episodic memory, language, recognition of facial emotion, sensory-perceptual functions, and executive functions. Compared with the controls, the NEAR group showed significantly poorer performance on nearly all of the cognitive tests and the MID group on about half of the cognitive tests (p = .05, Cohen's d NEAR as large as -1.17, MID as large as -0.61). One test even revealed significantly poorer performance in the FAR group (Cohen's d = -0.26). Individual tasks accounted for 0.2% to 9.7% of the variance in estimated proximity to diagnosis. Overall, the cognitive battery accounted for 34% of the variance; in comparison, the Unified Huntington's Disease Rating Scale motor score accounted for 11.7%. Neurocognitive tests are robust clinical indicators of the disease process prior to reaching criteria for motor diagnosis of HD.
ISSN:1931-1559
DOI:10.1037/a0020937